Matrix Metallopeptidase 9 Promotes Contraction in Human Uterine Myometrium
Reproductive Sciences · 2025
DOI: 10.1007/s43032-024-01778-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Reproductive Sciences, 2025. Verfasst von Craig C Ulrich und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, University of Nevada, Reno School of Medicine, 1664 North Virginia St., Reno, NV, 89557, USA. Hauptthemen laut MEDLINE: Uterine Contraction, Matrix Metalloproteinase 9, Myometrium. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of Child Health and Human Development, NIGMS NIH HHS, NICHD NIH HHS.
Abstract (Originalsprache)
Matrix metallopeptidase 9 (MMP9) is a secreted zinc-dependent peptidase known for extracellular remodeling. MMP9 is elevated in tissues from women experiencing preterm labor, and previous research has shown that the addition of combined matrix metallopeptidases 2 and 9 (MMP2/9) enhances uterine contractions. We hypothesized that adding MMP9 alone would enhance myometrial contractions and that specific MMP9 inhibition would suppress uterine contractions. In myometrial tissue from women undergoing term Caesarean sections, we observed an increased contractile response as measured by area under the curve over time in tissues treated with MMP9 compared to vehicle-treated controls ( p = 0.0003). This effect was primarily due to increased contraction frequency in MMP9-treated tissues compared to controls ( p < 0.0001). Specific inhibition of MMP9 with the highly selective MMP9 inhibitor 1 (AG-L-66085) reduced contractile responses in myometrial tissues from pregnant women. We observed a reduction in the oxytocin-induced contractile response as measured by area under the curve over time ( p < 0.0001) and contraction amplitude ( p < 0.0068) in AG-L-66085-treated tissues compared to vehicle-treated controls. To determine the effects of MMP9 inhibition in the absence of exogenous oxytocin, we tested the effects of AG-L-66085 on spontaneous contractions. The area under the curve ( p = 0.0415) and amplitude ( p = 0.0354) of spontaneous contractions were reduced in response to 1 μM AG-L-66085, and the inhibitory effects increased as the AG-L-66085 concentration increased. Together, these data support the hypothesis that elevated MMP9 promotes myometrial contractions and labor, while its inhibition promotes relaxation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, University of Nevada, Reno School of Medicine, 1664 North Virginia St., Reno, NV, 89557, USA.
- Department of Obstetrics and Gynecology, University of Nevada, Reno School of Medicine, 1664 North Virginia St., Reno, NV, 89557, USA.
- Department of Pharmacology, University of Nevada, Reno School of Medicine, 1664 North Virginia St., Reno, NV, 89557, USA. hburkin@med.unr.edu.
ORCID-Profile: Craig C Ulrich, Lauren L Parker, Janet A Lambert, Lexa Baldwin, Iain L O Buxton, Neda Etezadi-Amoli, Normand Leblanc, Heather R Burkin
Förderung
- National Institute of Child Health and Human Development
- NIGMS NIH HHS
- NICHD NIH HHS
Zitieren
APA
Ulrich, C. C., Parker, L. L., Lambert, J. A., Baldwin, L., Buxton, I. L. O., Etezadi-Amoli, N., Leblanc, N., & Burkin, H. R. (2025). Matrix Metallopeptidase 9 Promotes Contraction in Human Uterine Myometrium. Reproductive Sciences. https://doi.org/10.1007/s43032-024-01778-3
Vancouver
Ulrich CC, Parker LL, Lambert JA, Baldwin L, Buxton ILO, Etezadi-Amoli N, et al. Matrix Metallopeptidase 9 Promotes Contraction in Human Uterine Myometrium. Reproductive Sciences. 2025. doi:10.1007/s43032-024-01778-3
BibTeX
@article{Ulrich2025,
author = {Ulrich, Craig C and Parker, Lauren L and Lambert, Janet A and Baldwin, Lexa and Buxton, Iain L O and Etezadi-Amoli, Neda and Leblanc, Normand and Burkin, Heather R},
title = {Matrix Metallopeptidase 9 Promotes Contraction in Human Uterine Myometrium},
journal = {Reproductive Sciences},
year = {2025},
doi = {10.1007/s43032-024-01778-3}
}
EUVIMED